These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
201 related items for PubMed ID: 21721010
1. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, Chen H, Yin W, Liu J, Gu Y, Mo M, He J. J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010 [Abstract] [Full Text] [Related]
2. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival. Kim SH, Choi HY, Lee J, Son DS, Lee HS, Song IS, Lim YS, Hong YS, Kim J, Choi YS. J Surg Oncol; 2007 Mar 15; 95(4):337-46. PubMed ID: 17326127 [Abstract] [Full Text] [Related]
3. Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Lin Q, Li M, Shen ZY, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY, Chen M. Jpn J Clin Oncol; 2010 Jul 15; 40(7):670-6. PubMed ID: 20382636 [Abstract] [Full Text] [Related]
4. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer. Li L, Mei TH, Zhou XD, Zhang XG. Ai Zheng; 2009 Jan 15; 28(1):60-3. PubMed ID: 19448419 [Abstract] [Full Text] [Related]
5. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G. Cancer; 2005 Apr 15; 103(8):1676-84. PubMed ID: 15754326 [Abstract] [Full Text] [Related]
6. Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer. Miyoshi K, Moriyama S, Kunitomo T, Nawa S. J Thorac Cardiovasc Surg; 2009 Feb 15; 137(2):429-34. PubMed ID: 19185165 [Abstract] [Full Text] [Related]
7. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer. Hsu CP, Shen GH, Ko JL. Lung Cancer; 2006 Jun 15; 52(3):349-57. PubMed ID: 16569461 [Abstract] [Full Text] [Related]
8. Accuracy and prognostic impact of a vessel invasion grading system for stage IA non-small cell lung cancer. Hashizume S, Nagayasu T, Hayashi T, Hidaka S, Tsuchiya T, Tagawa T, Yamasaki N, Furukawa K, Matsumoto K, Miyazaki T. Lung Cancer; 2009 Sep 15; 65(3):363-70. PubMed ID: 19157635 [Abstract] [Full Text] [Related]
9. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS, Lee KY. Jpn J Clin Oncol; 2006 May 15; 36(5):263-8. PubMed ID: 16735371 [Abstract] [Full Text] [Related]
10. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Clin Cancer Res; 2000 Mar 15; 6(3):790-7. PubMed ID: 10741698 [Abstract] [Full Text] [Related]
11. Nonanatomic prognostic factors in resected nonsmall cell lung carcinoma: the importance of perineural invasion as a new prognostic marker. Sayar A, Turna A, Solak O, Kiliçgün A, Urer N, Gürses A. Ann Thorac Surg; 2004 Feb 15; 77(2):421-5. PubMed ID: 14759409 [Abstract] [Full Text] [Related]
12. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD, Wu QL, Ling P, Chen M, Xie ZM, Hu Y, Rong TH. J Clin Oncol; 2009 Mar 01; 27(7):1091-9. PubMed ID: 19188679 [Abstract] [Full Text] [Related]
14. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T. Anticancer Res; 2000 Mar 01; 20(2B):1311-6. PubMed ID: 10810441 [Abstract] [Full Text] [Related]
16. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Iniesta P, Morán A, De Juan C, Gómez A, Hernando F, García-Aranda C, Frías C, Díaz-López A, Rodríguez-Jiménez FJ, Balibrea JL, Benito M. Oncol Rep; 2007 Jan 01; 17(1):217-23. PubMed ID: 17143501 [Abstract] [Full Text] [Related]
17. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Cox G, Jones JL, O'Byrne KJ. Clin Cancer Res; 2000 Jun 01; 6(6):2349-55. PubMed ID: 10873086 [Abstract] [Full Text] [Related]
18. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Zheng S, Chang Y, Hodges KB, Sun Y, Ma X, Xue Y, Williamson SR, Lopez-Beltran A, Montironi R, Cheng L. Anticancer Res; 2010 Mar 01; 30(3):713-8. PubMed ID: 20392988 [Abstract] [Full Text] [Related]
19. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Takemoto N, Tada M, Hida Y, Asano T, Cheng S, Kuramae T, Hamada J, Miyamoto M, Kondo S, Moriuchi T. Lung Cancer; 2007 Dec 01; 58(3):376-83. PubMed ID: 17714826 [Abstract] [Full Text] [Related]
20. [Analysis of prognostic factors in 1826 patients with completely resected non-small cell lung cancer]. Gao YS, Xing XZ, Shao K, Feng XL, He J. Zhonghua Zhong Liu Za Zhi; 2008 Feb 01; 30(2):134-7. PubMed ID: 18646698 [Abstract] [Full Text] [Related] Page: [Next] [New Search]